Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin in previously treated advanced urothelial cancer
NCT03219333Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of enfortumab vedotin in urothelial carcinoma (UC), sponsored by Astellas Pharma. Started Oct 2017; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03219333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219333.